colonbroom.glp 1 GLP-1 Supplement & Weight Support ColonBroom - GLP-1 Booster -

Globally, 90% of diabetes patients have TIIDM

Based on this review, evidence from head-to-head and insulin-comparator trials demonstrates that dual GIP/GLP-1 co-agonism consistently overcomes metabolic plateaus that result from single-pathway therapy, producing superior glycated hemoglobin reduction, bariatric-level weight loss (up to 25.3%), and robust macrovascular and heart failure protection, including a 38% reduction in composite cardiovascular risk among patients with heart failure with preserved ejection fraction (HFpEF)

For GLP-1 Users: GLP-1 medications actively slow gastric emptying, frequently leading to stubborn constipation

Eli Lilly became the first healthcare or pharma company to reach a $1 trillion valuation

The current report aims to present an overview of current knowledge on GLP-1 RAs based on pragmatic review of the available clinical evidence